Advertisement Synthon doses first patient in Phase I trial of cancer drug SYD985 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Synthon doses first patient in Phase I trial of cancer drug SYD985

Synthon Biopharmaceuticals (Synthon) has started dosing patients with its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985, in a Phase I trial to treat metastatic solid tumors.

Patient enrollment in the trial is being carried out at European oncology centers such as Radboud University Medical Center in the Netherlands), the Jules Bordet Institute in Belgium and the Institute of Cancer Research at The Royal Marsden Hospital in the UK.

The company will enroll around 76 patients with more centers expected to be added to the trial in 2015.

Synthon CEO Jacques Lemmens said: "We believe SYD985 has the potential to at least double the current breast cancer population eligible for HER2-based ADC treatment.

"If successful, it could provide new treatment options for cancer patients with a high unmet medical need, including triple negative breast cancer patients."

In the trial’s dose escalation part, safety and efficacy of SYD985 will be evaluated in patients with locally advanced or metastatic solid tumors of any origin, while in the expanded cohort part, only patients with breast and gastric cancer will be enrolled.

The expanded cohorts will include patients currently indicated for HER2-targeted treatment as well as patients with HER2 2+ and HER2 1+ breast cancer for whom there currently is no effective anti-HER2 therapy available.